Combination of the Phosphodiesterase Inhibitors Sildenafil and Milrinone Induces Cardioprotection With Various Conditioning Strategies.


Journal

Journal of cardiovascular pharmacology
ISSN: 1533-4023
Titre abrégé: J Cardiovasc Pharmacol
Pays: United States
ID NLM: 7902492

Informations de publication

Date de publication:
12 2020
Historique:
pubmed: 2 10 2020
medline: 6 7 2021
entrez: 1 10 2020
Statut: ppublish

Résumé

Ischemic preconditioning and postconditioning are strong measures preserving the heart against ischemia-reperfusion injury in experimental setting but are too invasive and impractical for clinical routine. The cardioprotective effects of ischemic preconditioning and postconditioning can be imitated pharmacologically, for example, with the phosphodiesterase inhibitors sildenafil and milrinone. We hypothesize that sildenafil-induced preconditioning is concentration dependent and further that a combined treatment of "nonprotective" versus "protective" concentrations of sildenafil and milrinone leads to a significant infarct size reduction. Experiments were performed on isolated hearts of male Wistar rats, randomized into 12 groups, mounted onto a Langendorff system, and perfused with Krebs-Henseleit buffer. All hearts underwent 33 minutes ischemia and 60 minutes of reperfusion. For determination of a concentration-dependent effect of sildenafil, hearts were perfused with increasing concentrations of sildenafil (0.1-1 µM) over 10 minutes before ischemia. In a second series of experiments, hearts were treated with 0.3 µM sildenafil or 1 µM milrinone as the "protective" concentrations. A higher concentration of respective drugs did not further reduce infarct size. In addition, a combination of "protective" and "nonprotective" concentrations of sildenafil and milrinone was applied. Sildenafil and milrinone in lower concentrations led to significant infarct size reduction, whereas combining both substances in cardioprotective concentrations did not enhance this effect. Sildenafil in a concentration of 0.3 µM induces myocardial protection. Furthermore, treatment with sildenafil and milrinone in lower concentrations had an equally strong cardioprotective effect regarding infarct size reduction compared with the administration of "protective" concentrations.

Identifiants

pubmed: 33002964
doi: 10.1097/FJC.0000000000000919
pii: 00005344-202012000-00006
doi:

Substances chimiques

Phosphodiesterase 3 Inhibitors 0
Phosphodiesterase 5 Inhibitors 0
Sildenafil Citrate BW9B0ZE037
Milrinone JU9YAX04C7

Types de publication

Comparative Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

684-691

Références

WHO. The 10 Leading Causes of Death in the World, 2000 and 2012. 2018. Available at: https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death. Accessed May 28, 2020.
Yellon DM, Hausenloy DJ. Myocardial reperfusion injury. N Engl J Med. 2007;357:1121–1135.
Caricati-Neto A, Errante PR, Menezes-Rodrigues FS. Recent advances in pharmacological and non-pharmacological strategies of cardioprotection. Int J Mol Sci. 2019;20:4002.
Feneck R. Phosphodiesterase inhibitors and the cardiovascular system. Contin Educ Anaesth Crit Care Pain. 2007;7:203–207.
de Cheffoy de Courcelles D, de Loore K, Freyne E, et al. Inhibition of human cardiac cyclic AMP-phosphodiesterases by R 80122, a new selective cyclic AMP-phosphodiesterase III inhibitor: a comparison with other cardiotonic compounds. J Pharmacol Exp Ther. 1992;263:6–14.
Rong LQ, Rahouma M, Abouarab A, et al. Intravenous and inhaled milrinone in adult cardiac surgery patients: a pairwise and network meta-analysis. J Cardiothorac Vasc Anesth. 2019;33:663–673.
Sanada S, Kitakaze M, Papst PJ, et al. Cardioprotective effect afforded by transient exposure to phosphodiesterase III inhibitors: the role of protein kinase A and p38 mitogen-activated protein kinase. Circulation. 2001;104:705–710.
Raupach A, Reinle J, Stroethoff M, et al. Milrinone-induced pharmacological preconditioning in cardioprotection: hints for a role of mitochondrial mechanisms. J Clin Med. 2019;8:507.
Behmenburg F, Trefz L, Dorsch M, et al. Milrinone-induced postconditioning requires activation of mitochondrial Ca(2+)-sensitive potassium (mBKCa) channels. J Cardiothorac Vasc Anesth. 2018;32:2142–2148.
Galiè N, Ghofrani HA, Torbicki A, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med. 2005;353:2148–2157.
Peixoto CA, Gomes FO. The role of phosphodiesterase-5 inhibitors in prostatic inflammation: a review. J Inflamm. 2015;12:54.
Salloum FN, Abbate A, Das A, et al. Sildenafil (Viagra) attenuates ischemic cardiomyopathy and improves left ventricular function in mice. Am J Physiol Heart Circ Physiol. 2008;294:H1398–H1406.
Hutchings DC, Anderson SG, Caldwell JL, et al. Phosphodiesterase-5 inhibitors and the heart: compound cardioprotection? Heart. 2018;104:1244–1250.
Das A, Xi L, Kukreja RC. Protein kinase G-dependent cardioprotective mechanism of phosphodiesterase-5 inhibition involves phosphorylation of ERK and GSK3beta. J Biol Chem. 2008;283:29572–29585.
Kukreja RC, Salloum F, Das A, et al. Pharmacological preconditioning with sildenafil: basic mechanisms and clinical implications. Vascul Pharmacol. 2005;42:219–232.
Salloum F, Yin C, Xi L, et al. Sildenafil induces delayed preconditioning through inducible nitric oxide synthase-dependent pathway in mouse heart. Circ Res. 2003;92:595–597.
Prins KW, Thenappan T. World health organization group I pulmonary hypertension: epidemiology and pathophysiology. Cardiol Clin. 2016;34:363–374.
Percie du Sert N, Ahluwalia A, Alam S, et al. Reporting animal research: explanation and elaboration for the ARRIVE guidelines 2.0. PLoS Biol. 2020;18:e3000411.
Heinen A, Strothoff M, Schmidt A, et al. Pharmacological options to protect the aged heart from ischemia and reperfusion injury by targeting the PKA-BK(Ca) signaling pathway. Exp Gerontol. 2014;56:99–105.
Behmenburg F, Dorsch M, Huhn R, et al. Impact of mitochondrial Ca2+-sensitive potassium (mBKCa) channels in sildenafil-induced cardioprotection in rats. PLoS One. 2015;10:e0144737–e.
Tantini B, Manes A, Fiumana E, et al. Antiproliferative effect of sildenafil on human pulmonary artery smooth muscle cells. Bas Res Cardiol. 2005;100:131–138.
Das A, Durrant D, Salloum FN, et al. PDE5 inhibitors as therapeutics for heart disease, diabetes and cancer. Pharmacol Ther. 2015;147:12–21.
Heringlake M, Schön J, Pliet T, et al. Prevalence, diagnosis, perioperative monitoring and treatment of right ventricular dysfunction and/or pulmonary arterial hypertension in cardiac surgical patients in Germany-a postal survey. Thorac Cardiovasc Surg. 2017;65:593–600.
Fox C, Kalarickal PL, Yarborough MJ, et al. Perioperative management including new pharmacological vistas for patients with pulmonary hypertension for noncardiac surgery. Curr Opin Anaesthesiol. 2008;21:467–472.
Cohn JN, Ferrari R, Sharpe N. Cardiac remodeling—concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling. J Am Coll Cardiol. 2000;35:569–582.
Goldstein I, Lue TF, Padma-Nathan H, et al. Oral sildenafil in the treatment of erectile dysfunction. N Eng J Med. 1998;338:1397–1404.
Chong LYZ, Satya K, Kim B, et al. Milrinone dosing and a culture of caution in clinical practice. Cardiol Rev. 2018;26:35–42.
Lu Y, Dong CS, Yu JM, et al. Morphine reduces the threshold of remote ischemic preconditioning against myocardial ischemia and reperfusion injury in rats: the role of opioid receptors. J Cardiothorac Vasc Anesth. 2012;26:403–406.
Pagel PS, Krolikowski JG, Amour J, et al. Morphine reduces the threshold of helium preconditioning against myocardial infarction: the role of opioid receptors in rabbits. J Cardiothorac Vasc Anesth. 2009;23:619–624.
Ludwig LM, Patel HH, Gross GJ, et al. Morphine enhances pharmacological preconditioning by isoflurane: role of mitochondrial K(ATP) channels and opioid receptors. Anesthesiology. 2003;98:705–711.
Huang MH, Wu Y, Nguyen V, et al. Heart protection by combination therapy with esmolol and milrinone at late-ischemia and early reperfusion. Cardiovasc Drugs Ther. 2011;25:223–232.
Wang X, Fisher PW, Xi L, et al. Essential role of mitochondrial Ca2+-activated and ATP-sensitive K+ channels in sildenafil-induced late cardioprotection. J Mol Cell Cardiol. 2008;44:105–113.
Boengler K, Lochnit G, Schulz R. Mitochondria “THE” target of myocardial conditioning. Am J Physiol Heart Circ Physiol. 2018;315:H1215–h31.
Di Lisa F, Menabò R, Canton M, et al. Opening of the mitochondrial permeability transition pore causes depletion of mitochondrial and cytosolic NAD+ and is a causative event in the death of myocytes in postischemic reperfusion of the heart. J Biol Chem. 2001;276:2571–2575.
Stief CG, Uckert S, Becker AJ, et al. Effects of sildenafil on cAMP and cGMP levels in isolated human cavernous and cardiac tissue. Urology. 2000;55:146–150.
Zaccolo M, Movsesian MA. cAMP and cGMP signaling cross-talk: role of phosphodiesterases and implications for cardiac pathophysiology. Circ Res. 2007;100:1569–1578.
Lee KH, Kwon SJ, Woo JS, et al. Effects of sildenafil on nanostructural and nanomechanical changes in mitochondria in an ischaemia-reperfusion rat model. Clin Exp Pharmacol Physiol. 2014;41:763–768.

Auteurs

Carolin Torregroza (C)

Department of Anesthesiology, University Hospital Duesseldorf, Moorenstr, Duesseldorf, Germany.
Department of Anesthesiology, Amsterdam University Medical Centers (AUMC), Meiberdreef, Amsterdam, Netherlands; and.

Kitti Maas (K)

Department of Anesthesiology, University Hospital Duesseldorf, Moorenstr, Duesseldorf, Germany.

Katharina Feige (K)

Department of Anesthesiology, University Hospital Duesseldorf, Moorenstr, Duesseldorf, Germany.

Annika Raupach (A)

Department of Anesthesiology, University Hospital Duesseldorf, Moorenstr, Duesseldorf, Germany.

Martin Stroethoff (M)

Department of Anesthesiology, University Hospital Duesseldorf, Moorenstr, Duesseldorf, Germany.

André Heinen (A)

Institute of Cardiovascular Physiology, Heinrich-Heine-University Duesseldorf, Universitaetsstr, Duesseldorf, Germany.

Markus W Hollmann (MW)

Department of Anesthesiology, Amsterdam University Medical Centers (AUMC), Meiberdreef, Amsterdam, Netherlands; and.

Ragnar Huhn (R)

Department of Anesthesiology, University Hospital Duesseldorf, Moorenstr, Duesseldorf, Germany.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH